Tag Archives: ATRC

Atricure (ATRC) Gets a Buy Rating from BTIG

In a report released yesterday, Sean Lavin from BTIG maintained a Buy rating on Atricure (ATRC – Research Report), with a price target of $35. The company’s shares closed last Monday at $30.62. According to TipRanks.com, Lavin is a 4-star

Analysts Offer Insights on Healthcare Companies: Atricure (NASDAQ: ATRC) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC – Research Report) and BioMarin Pharmaceutical Inc. (BMRN – Research Report) with bullish sentiments. Atricure (ATRC) In a report released

Atricure (ATRC) Receives a Buy from Needham

In a report released today, Michael Matson from Needham reiterated a Buy rating on Atricure (ATRC – Research Report), with a price target of $39. The company’s shares closed yesterday at $27.39. Matson observed: “ATRC shares are down 14% over

BTIG Reaffirms Their Hold Rating on Atricure (ATRC)

BTIG analyst Sean Lavin maintained a Hold rating on Atricure (ATRC – Research Report) yesterday. The company’s shares opened today at $29.27. Lavin commented: “Neutral ATRC reported full Q4 results last week while we were hosting our annual Snowbird conference.

Needham Keeps Their Buy Rating on Atricure (ATRC)

In a report released today, Michael Matson from Needham reiterated a Buy rating on Atricure (NASDAQ: ATRC), with a price target of $39. The company’s shares closed yesterday at $32.54. Matson observed: “On 10/3/18, ATRC preannounced 3Q18 revenue that was

Needham Maintains a Buy Rating on Atricure (ATRC)

In a report released today, Michael Matson from Needham maintained a Buy rating on Atricure (NASDAQ: ATRC), with a price target of $39. The company’s shares closed yesterday at $30.01. Matson wrote: “ATRC announced on 8/28/18 that it had completed